Oncopeptides (ONCO) Resumen de Acciones
Oncopeptides AB (publ), empresa biotecnológica, se dedica a la investigación, desarrollo y comercialización de terapias dirigidas para enfermedades hematológicas de difícil tratamiento en Estados Unidos, Europa y a escala internacional. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 3/6 |
| Crecimiento futuro | 2/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 5/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
ONCO Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
Competidores de Oncopeptides AB (publ)
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | SEK 1.71 |
| Máximo en las últimas 52 semanas | SEK 6.96 |
| Mínimo de 52 semanas | SEK 1.26 |
| Beta | -1.31 |
| Cambio en 1 mes | 35.04% |
| Variación en 3 meses | 8.57% |
| Cambio de 1 año | 13.16% |
| Variación en 3 años | -78.99% |
| Variación en 5 años | -98.07% |
| Variación desde la OPV | -96.02% |
Noticias y actualizaciones recientes
Recent updates
ONCO: Rights Issue And Glioblastoma Study Will Support Bullish Long Term View
Analysts have maintained their SEK fair value estimate for Oncopeptides at SEK 2.80, while fine tuning assumptions for the discount rate, profit margin, and future P/E. This reflects updated views on the company’s risk profile and earnings potential without changing the headline price target.ONCO: Rights Issue And New Studies Will Support Bullish Long Term View
Analysts have modestly adjusted their SEK price target for Oncopeptides, reflecting small refinements to discount rate, profit margin assumptions, and future P/E inputs rather than a shift in the core fair value view. What's in the News Oncopeptides plans to support the MARINA real world evidence study of Pepaxti in relapsed, refractory multiple myeloma in Germany, targeting around 50 patients across about 25 sites, with iOMEDICO as sponsor and coordinator and first patient enrolment planned for the second quarter of 2026 (Key Developments).ONCO: Rights Offering And 2025 Sales Guidance Will Support Bullish View
Analysts have kept their SEK price target for Oncopeptides effectively unchanged, pointing to stable fair value assumptions and only marginal tweaks to inputs such as the discount rate, forecast revenue growth, profit margin and future P/E multiple. What's in the News Oncopeptides has filed a follow on equity offering of Ordinary Shares, targeting SEK 200.4 million through a rights offering of 129,283,736 shares at SEK 1.55 per share (Key Developments).ONCO: Rights Issue And 2025 Sales Outlook Will Support Bullish View
Analysts have adjusted their price target on Oncopeptides to SEK 2.80. The change is largely tied to updated assumptions around the discount rate, profit margin, and future P/E, rather than a shift in estimated fair value.ONCO: Rights Issue And 2025 Sales Guidance Will Support Bullish Outlook
Analysts have trimmed their price target on Oncopeptides to SEK 2.80 from SEK 4.75, reflecting updated assumptions for slightly lower revenue growth, a marginally softer profit margin, a higher discount rate, and a reduced future P/E multiple. What's in the News Oncopeptides AB (publ) has filed a follow on equity offering of approximately SEK 200.4m through a rights offering of 129,283,736 ordinary shares at SEK 1.55 per share (Key Developments).ONCO: Future Sales Guidance Will Support Bullish View On Upcoming Results
Analysts have cut their price target on Oncopeptides to €4.75 from €5.50, reflecting updated assumptions around revenue growth, profit margins, a higher discount rate, and a higher future P/E multiple. What's in the News Oncopeptides issued sales guidance for the fourth quarter 2025.
ONCO: NK Cell Platform Progress Will Drive Future Risk Reward Repricing
Analysts have reduced their price target for Oncopeptides from 5.0 to 4.5, reflecting a fair value adjustment driven by shifts in projected revenue growth, higher discount rates, stronger profit margin assumptions, and a lower future P/E estimate. What's in the News Oncopeptides issued sales guidance for the fourth quarter and full year 2025, with expected Q4 2025 net sales of SEK 18.6 million and full year 2025 net sales of SEK 71.2 million, both described by the company as higher compared with 2024 (Corporate guidance).ONCO: NK Cell Platform Progress And Expert Guidance Will Shape Future Risk Reward
Analysts have modestly lowered their future P/E assumption for Oncopeptides from 38.59x to 36.58x, keeping fair value at €5.00. They have fine tuned expectations for revenue growth and profit margins while making a slight adjustment to the discount rate.
ONCO: Improved Profitability And NK Cell Platform Will Drive Long-Term Upside
Analysts have raised their price target on Oncopeptides from approximately SEK 4.50 to SEK 5.50 per share, citing expectations of stronger long term profitability, supported by higher projected profit margins and a lower future price to earnings multiple, despite slightly tempered revenue growth assumptions and a modestly higher discount rate. What's in the News Panel of leading multiple myeloma experts publishes clinical recommendations in Annals of Hematology on optimal use of Pepaxti (melflufen), reinforcing its role as an important option for relapsed, refractory multiple myeloma, including elderly and high risk patients, with a manageable safety profile (company announcement).ONCO: Future NK Platform And Equity Raise Will Shape Risk Reward Profile
Analysts have modestly raised their price target on Oncopeptides to align with a fair value approaching $5.00 per share, citing a higher required discount rate, more conservative revenue growth and margin assumptions, and a structurally higher future P/E multiple. Taken together, these factors imply a more cautiously optimistic risk reward profile.Agreements In Europe And Japan Will Unlock Global Markets
The notable increase in Oncopeptides' fair value target is primarily driven by a higher forecasted future P/E multiple, despite a marginal dip in revenue growth expectations, with the analyst consensus price target rising from SEK2.73 to SEK3.25. What's in the News Strategic partnership with SD Pharma enhances Pepaxti's hospital reach in Spain without upfront costs, starting Q3 2025.A Look At The Fair Value Of Oncopeptides AB (publ) (STO:ONCO)
Key Insights Oncopeptides' estimated fair value is kr5.77 based on Dividend Discount Model Oncopeptides' kr6.00 share...
Agreements In Europe And Japan Will Unlock Global Markets
Strategic agreements in Europe and potential licensing in Japan will unlock major markets, enhancing future earnings and revenue growth.An Intrinsic Calculation For Oncopeptides AB (publ) (STO:ONCO) Suggests It's 45% Undervalued
Key Insights Using the Dividend Discount Model, Oncopeptides fair value estimate is kr5.43 Oncopeptides is estimated to...Oncopeptides (STO:ONCO) Will Have To Spend Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Oncopeptides (STO:ONCO) Has Debt But No Earnings; Should You Worry?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...We Think Oncopeptides (STO:ONCO) Needs To Drive Business Growth Carefully
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Rentabilidad de los accionistas
| ONCO | SE Biotechs | Mercado SE | |
|---|---|---|---|
| 7D | -3.9% | -1.8% | -2.1% |
| 1Y | 13.2% | 20.5% | 9.3% |
Rentabilidad vs. Industria: Los resultados de ONCO fueron inferiores a los de la industria Swedish Biotechs, que obtuvo un rendimiento del 20.5% el año pasado.
Rentabilidad vs. Mercado: ONCO superó al mercado Swedish, que obtuvo un rendimiento del 9.3% el año pasado.
Volatilidad de los precios
| ONCO volatility | |
|---|---|
| ONCO Average Weekly Movement | 14.8% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in SE Market | 13.9% |
| 10% least volatile stocks in SE Market | 3.5% |
Precio estable de las acciones: El precio de las acciones de ONCO ha sido volátil durante los últimos 3 meses en comparación con el mercado Swedish.
Volatilidad a lo largo del tiempo: La volatilidad semanal de ONCO(15%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de las acciones de Swedish.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2000 | 75 | Sofia Heigis | www.oncopeptides.com/sv |
Oncopeptides AB (publ), empresa biotecnológica, se dedica a la investigación, desarrollo y comercialización de terapias dirigidas para enfermedades hematológicas difíciles de tratar en Estados Unidos, Europa y el resto del mundo. Su principal producto candidato es Pepaxti (melflufeno), un fármaco conjugado para el tratamiento del mieloma múltiple refractario recidivante en pacientes adultos. Su plataforma PDC está diseñada con dos componentes, un portador peptídico y una carga útil citotóxica que utiliza el metabolismo alterado de las células cancerosas para hidrolizar el PDC en metabolitos hidrofílicos activos, lo que conduce a un enriquecimiento en células cancerosas.
Resumen de fundamentos de Oncopeptides AB (publ)
| Estadísticas fundamentales de ONCO | |
|---|---|
| Capitalización bursátil | SEK 676.34m |
| Beneficios(TTM) | -SEK 221.10m |
| Ingresos (TTM) | SEK 83.24m |
¿Está ONCO sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de ONCO | |
|---|---|
| Ingresos | SEK 83.24m |
| Coste de los ingresos | SEK 2.86m |
| Beneficio bruto | SEK 80.38m |
| Otros gastos | SEK 301.48m |
| Beneficios | -SEK 221.10m |
Últimos beneficios comunicados
Mar 31, 2026
Próxima fecha de beneficios
Aug 27, 2026
| Beneficios por acción (BPA) | -0.56 |
| Margen bruto | 96.57% |
| Margen de beneficio neto | -265.63% |
| Ratio deuda/patrimonio | 170.3% |
¿Cómo se ha desempeñado ONCO a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/06/09 09:28 |
| Precio de las acciones al final del día | 2026/06/09 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Oncopeptides AB (publ) está cubierta por 7 analistas. 3 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Erik Hultgård | Carnegie Investment Bank AB |
| Patrik Ling | DNB Carnegie |
| Erik Hultgård | DNB Carnegie |